Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
Open Access
- 1 March 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (3), 311-317
- https://doi.org/10.1097/jto.0b013e3181989bd2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapyCancer, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Long-Standing Debate on Cisplatin- Versus Carboplatin-Based Chemotherapy in the Treatment of Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Methodological aspects of current problems in target-based anticancer drug developmentInternational Journal of Clinical Oncology, 2006
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- New cytotoxic agents: a review of the literatureCritical Reviews in Oncology/Hematology, 2005
- Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- On the Use of Surrogate End Points in Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 2000
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995